Skip to Main Content

With biotech’s constant parade of venture financings, Wall Street debuts, and nine-figure buyouts, it’s easy to forget that constant boom wasn’t always the norm.

It all kicked off in 2013, when a surge in investor optimism made it unprecedentedly easy for biotech companies to go public, which sparked a rush of VC dollars and created a virtuous cycle that lined the pockets of investors and set the stage for future initial public offerings.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

  • Interesting: this is my very first visit, having just subscribed to STAT, and the first article I click on is interrupted, first, by an ad (expected), then asking to upgrade if I want to finish the article. Thank you for inviting me to the top of the hierarchy, but “No, thanks!”

Comments are closed.